Buy Ipamorelin Research Peptide

What is Ipamorelin?

Ipamorelin is a selective growth-hormone-releasing peptide widely used in research. It works cleanly on the ghrelin receptor without raising cortisol or prolactin the way some other compounds do, which makes it a popular tool for studying growth-hormone release on its own.

• A five-amino-acid peptide widely used in growth-hormone research
• Works selectively on the ghrelin receptor (GHS-R1a) in published studies
• Studied in animal research for its effects on signaling, bone density and metabolism markers
• Often studied alongside GHRH-type compounds in growth-hormone research

For research use only. Not approved for human therapeutic use.

Ipamorelin (CAS 170851-70-4), also known by its developmental code NNC-26-0161, is a synthetic pentapeptide growth hormone secretagogue with the molecular formula C38H49N9O5 and a molecular weight of 711.86 g/mol. Defined by the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, Ipamorelin incorporates an alpha-aminoisobutyric acid (Aib) residue at position 1 and a D-2-Naphthylalanine residue at position 3, structural features that distinguish it from earlier generation secretagogues. Produced via solid-phase peptide synthesis, NNC-26-0161 acts as a selective agonist at the ghrelin receptor (GHS-R1a) and is widely referenced in preclinical growth hormone research.

Ipamorelin has been extensively investigated in preclinical endocrinology and receptor pharmacology research. In vitro receptor pharmacology studies in pituitary cell models have examined its binding characteristics at the GHS-R1a receptor, with published research documenting GH-related signalling pathway activation without concurrent stimulation of adrenocorticotropic hormone (ACTH) or cortisol release in comparative secretagogue panels including GHRP-6 and GHRP-2 [1]. Rodent model studies have further investigated the compound’s interaction with pituitary somatotroph populations, examining dose-response characteristics of GH-mediated effects under controlled experimental conditions [2]. Ipamorelin’s selectivity profile has made it a key reference compound in structure-activity relationship research across the secretagogue class.

Ipamorelin is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552–61. .PubMed PMID: 98498222Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999 Apr;9(2):106–13. .PubMed PMID: 10373343

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →

Ipamorelin (CAS 170851-70-4), also known by its developmental code NNC-26-0161, is a synthetic pentapeptide growth hormone secretagogue with the molecular formula C38H49N9O5 and a molecular weight of 711.86 g/mol. Defined by the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, Ipamorelin incorporates an alpha-aminoisobutyric acid (Aib) residue at position 1 and a D-2-Naphthylalanine residue at position 3, structural features that distinguish it from earlier generation secretagogues. Produced via solid-phase peptide synthesis, NNC-26-0161 acts as a selective agonist at the ghrelin receptor (GHS-R1a) and is widely referenced in preclinical growth hormone research.

Ipamorelin has been extensively investigated in preclinical endocrinology and receptor pharmacology research. In vitro receptor pharmacology studies in pituitary cell models have examined its binding characteristics at the GHS-R1a receptor, with published research documenting GH-related signalling pathway activation without concurrent stimulation of adrenocorticotropic hormone (ACTH) or cortisol release in comparative secretagogue panels including GHRP-6 and GHRP-2 [1]. Rodent model studies have further investigated the compound’s interaction with pituitary somatotroph populations, examining dose-response characteristics of GH-mediated effects under controlled experimental conditions [2]. Ipamorelin’s selectivity profile has made it a key reference compound in structure-activity relationship research across the secretagogue class.

Ipamorelin is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552–61. .PubMed PMID: 98498222Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999 Apr;9(2):106–13. .PubMed PMID: 10373343

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →CAS Number170851-70-4Molecular Weight711.85 g/molPurity≥98%Physical FormLyophilised PowderManufacturingManufactured in an ISO9001 Certified LaboratoryTestingHPLC + MS-UPLCSKUIPA

Lyophilised powder: store at -20 °C or below, away from light and moisture. Once reconstituted in an appropriate laboratory diluent (e.g. sterile water, PBS, or assay buffer), store at 2–8 °C and use within the validated period for your protocol. Do not refreeze.

Ipamorelin (CAS 170851-70-4), also known by its developmental code NNC-26-0161, is a synthetic pentapeptide growth hormone secretagogue with the molecular formula C38H49N9O5 and a molecular weight of 711.86 g/mol. Defined by the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, Ipamorelin incorporates an alpha-aminoisobutyric acid (Aib) residue at position 1 and a D-2-Naphthylalanine residue at position 3, structural features that distinguish it from earlier generation secretagogues. Produced via solid-phase peptide synthesis, NNC-26-0161 acts as a selective agonist at the ghrelin receptor (GHS-R1a) and is widely referenced in preclinical growth hormone research.

Ipamorelin has been extensively investigated in preclinical endocrinology and receptor pharmacology research. In vitro receptor pharmacology studies in pituitary cell models have examined its binding characteristics at the GHS-R1a receptor, with published research documenting GH-related signalling pathway activation without concurrent stimulation of adrenocorticotropic hormone (ACTH) or cortisol release in comparative secretagogue panels including GHRP-6 and GHRP-2 [1]. Rodent model studies have further investigated the compound’s interaction with pituitary somatotroph populations, examining dose-response characteristics of GH-mediated effects under controlled experimental conditions [2]. Ipamorelin’s selectivity profile has made it a key reference compound in structure-activity relationship research across the secretagogue class.

Ipamorelin is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552–61. .PubMed PMID: 98498222Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999 Apr;9(2):106–13. .PubMed PMID: 10373343

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →CAS Number170851-70-4Molecular Weight711.85 g/molPurity≥98%Physical FormLyophilised PowderManufacturingManufactured in an ISO9001 Certified LaboratoryTestingHPLC + MS-UPLCSKUIPA

Lyophilised powder: store at -20 °C or below, away from light and moisture. Once reconstituted in an appropriate laboratory diluent (e.g. sterile water, PBS, or assay buffer), store at 2–8 °C and use within the validated period for your protocol. Do not refreeze.